More Side Effects With CRT Plus Metformin in Head, Neck Cancer

This article originally appeared here.
Share this content:
More Side Effects With CRT Plus Metformin in Head, Neck Cancer
More Side Effects With CRT Plus Metformin in Head, Neck Cancer

FRIDAY, May 5, 2017 (HealthDay News) -- Patients with advanced head and neck cancer undergoing chemoradiotherapy (CRT) and receiving metformin experience more side effects than patients not on metformin, according to research published online April 27 in Head & Neck.

Pei-Hung Chang, M.D., from the Chang Gung Memorial Hospital in Taoyuan City, Taiwan, and colleagues conducted a retrospective analysis involving 252 patients with stages III, IVA, and IVB head and neck cancer undergoing concurrent CRT with and without metformin treatment. The authors compared the clinical characteristics, treatment tolerance, toxicities, and survival for the 39 patients with and the 219 patients without metformin treatment.

The researchers found that the clinical characteristics were similar between the groups, and disease-free and overall survival were nearly identical. Compared to those not receiving metformin, patients receiving metformin were less likely to tolerate cisplatin, had more weight loss, were likely to receive lower doses of radiotherapy, needed more feeding tube support, and had grade ≥3 nausea/vomiting and hematological toxicities.

"Patients with head and neck cancer undergoing concurrent CRT along with metformin treatment require more careful multidisciplinary assessment and supportive care to ensure successful completion of treatment and avoid treatment-related toxicities," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Actemra to Treat Giant Cell Arteritis

FDA Approves Actemra to Treat Giant Cell Arteritis

New indication provides the first FDA-approved therapy specific to this type of vasculitis

Trends in Teen Binge Drinking Still Raise Concerns

Trends in Teen Binge Drinking Still Raise Concerns

Even though frequent binge drinking among adolescents has dropped in past 25 years

ATS: First Abx Rx Doesn't Work for 25 of Pneumonia Cases

ATS: First Abx Rx Doesn't Work for ~25% ...

One in four adult patients do not respond to initial prescription of antibiotic treatment

is free, fast, and customized just for you!

Already a member?

Sign In Now »